Glassman Wealth Services boosted its position in Amgen Inc. (NASDAQ:AMGN) by 480.0% during the second quarter, Holdings Channel reports. The institutional investor owned 725 shares of the medical research company’s stock after buying an additional 600 shares during the period. Glassman Wealth Services’ holdings in Amgen were worth $110,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oak Associates Ltd. OH increased its position in Amgen by 0.9% in the second quarter. Oak Associates Ltd. OH now owns 212,615 shares of the medical research company’s stock worth $32,349,000 after buying an additional 1,905 shares in the last quarter. Eaton Vance Management increased its stake in shares of Amgen by 24.8% in the second quarter. Eaton Vance Management now owns 1,875,168 shares of the medical research company’s stock valued at $285,307,000 after buying an additional 372,803 shares during the period. OLD National Bancorp IN increased its stake in shares of Amgen by 91.4% in the second quarter. OLD National Bancorp IN now owns 3,820 shares of the medical research company’s stock valued at $581,000 after buying an additional 1,824 shares during the period. Financial Counselors Inc. increased its stake in shares of Amgen by 21.1% in the second quarter. Financial Counselors Inc. now owns 13,280 shares of the medical research company’s stock valued at $2,021,000 after buying an additional 2,314 shares during the period. Finally, Pegasus Partners Ltd. increased its stake in shares of Amgen by 15.3% in the second quarter. Pegasus Partners Ltd. now owns 14,420 shares of the medical research company’s stock valued at $2,194,000 after buying an additional 1,910 shares during the period. 79.15% of the stock is currently owned by institutional investors.

Amgen Inc. (NASDAQ:AMGN) traded up 0.71% during trading on Thursday, reaching $175.08. The company’s stock had a trading volume of 1,043,233 shares. The company’s 50 day moving average price is $171.97 and its 200 day moving average price is $159.77. Amgen Inc. has a 52 week low of $130.09 and a 52 week high of $176.64. The company has a market cap of $131.02 billion, a P/E ratio of 17.92 and a beta of 0.87.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same period last year, the business posted $2.57 EPS. Amgen’s revenue was up 5.9% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were paid a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 annualized dividend and a yield of 2.30%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.

AMGN has been the topic of several recent research reports. BMO Capital Markets reissued a “buy” rating and issued a $186.00 price target on shares of Amgen in a report on Tuesday, July 12th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $165.78 price target on the stock in a report on Wednesday, July 27th. Leerink Swann reissued a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Finally, Robert W. Baird reissued a “neutral” rating and issued a $157.00 price target on shares of Amgen in a report on Thursday, July 28th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $184.87.

In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.